어플

NH Investment & Securities Keeps 'Buy' Rating and 15,000 Won Target Price for ContentreeJoongAng, Predicts Market Interest Surge in H2

Business / Kim SangJin / 08/26/2024 03:30 AM

(Photo= Yonhap news)

 

[Alpha Biz= Reporter Kim Sangjin] On August 23, NH Investment & Securities reaffirmed its 'Buy' rating and target price of 15,000 won for ContentreeJoongAng, citing anticipated market interest in the second half of the year.

Currently, ContentreeJoongAng's market capitalization stands at 181.8 billion won, reflecting only the value of its theater division due to prolonged performance issues and lack of momentum, which have led to a weak stock price.

However, the firm expects momentum to recover with the upcoming release of major new content. High-profile sequels to global hits such as "Squid Game" and "Hellbound" are scheduled for release, which are anticipated to boost the company's market performance.

NH Investment & Securities noted that upcoming releases like "Hellbound 2" and "The Forest Where No One Is" are expected to attract significant attention and improve the broadcast division's momentum. Additionally, the positive stock trends of industry leader Netflix suggest a broader market recovery.

In the theater sector, high-expectation films like "Joker 2" and "Veteran 2" are set to premiere, further supporting the expected rebound.

The firm highlighted the seasonal peak effect and anticipates growth in performance and momentum for ContentreeJoongAng.

 

 

 

AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)

Related articles

[Exclusive] Samsung Electronics to Supply HBM3E 12-High Stacks to NVIDIA
DL E&C Executives Resign En Masse Following Fatal Construction Site Accident
POSCO Future M Terminates KRW 945 Billion ESS Cathode Material Supply Contract, Signs New LFP Partnership with CNGR
Hahn & Company Selects TKG Taekwang as Preferred Bidder for Sale of Semiconductor Parts Maker Solmix
Hyundai Motor Group Bolsters SDV and Autonomous Driving Capabilities with KRW 500.3 Billion Investment in 42dot
comments >

SNS